Turkey Company Roundup: Novartis Malaria Plans, MSD R&D Boost
This article was originally published in PharmAsia News
Executive Summary
Novartis aims to double its exports from Turkey in five years by locally producing a malaria drug, while MSD plans to channel more R&D investments to the country. Meanwhile, the CEO of a Turkish pharmaceutical company gets 30 months’ imprisonment from a U.S. federal court, Bayer faces a lawsuit in Turkey and Alvimedica gets U.S. FDA approval for two catheter products.